Milliman MedInsight Achieves ONC Certification, Advancing Value-Based Care Solutions in Healthcare
- Milliman MedInsight secures ONC certification for electronic Clinical Quality Measures, enhancing compliance and patient care.
- The certification validates Milliman MedInsight’s commitment to quality and security in healthcare technology solutions.
- Milliman MedInsight aims to improve clinical data integration, focusing on value-based care and healthcare transformation.
Milliman MedInsight Advances Value-Based Care with ONC Certification
Milliman MedInsight, a leading player in healthcare data and analytics, begins 2026 with significant momentum as it intensifies its commitment to value-based care. The organization recently secures certification from the Office of the National Coordinator for Health Information Technology (ONC) for its electronic Clinical Quality Measures (eCQM) as part of the Health IT Certification Program. This prestigious certification validates that Milliman MedInsight's solutions adhere to essential federal standards regarding capability, functionality, and security. As a result, this development simplifies reporting processes for healthcare organizations while enhancing patient care and ensuring compliance with regulatory requirements.
The ONC certification stands as a testament to Milliman MedInsight's dedication to quality and security in healthcare technology. Nicole Zilliox, the Director of Clinical Products at Milliman MedInsight, expresses pride in this achievement, emphasizing that it offers third-party validation of their solutions' effectiveness in supporting healthcare organizations with accurate eCQM and clinical data reporting. This certification not only reassures clients but also strengthens Milliman’s position as a trusted partner in navigating the complexities of healthcare reporting and compliance.
As part of its broader vision, Milliman MedInsight aims to empower healthcare providers, payers, and public health agencies through enhanced clinical data integration. This strategic focus involves consolidating data from diverse sources, including electronic health records (EHRs), claims, laboratories, and admission/discharge/transfer (ADT) systems. Rich Moyer, Chief Product Officer, highlights the critical role of reliable and timely data in transforming healthcare performance. Looking ahead, Milliman MedInsight plans to leverage its ONC certification and advanced integration strategies to facilitate actionable insights for healthcare organizations, promoting both clinical excellence and operational efficiency in an increasingly dynamic healthcare landscape.
Strategic Goals and Future Directions
Milliman MedInsight's commitment to enhancing clinical data integration is set to lead to significant improvements in care quality, operational efficiency, and financial performance for healthcare providers. By focusing on value-based care, the organization positions itself as a critical player in the ongoing transformation of healthcare delivery systems.
The ONC certification not only fortifies Milliman MedInsight's reputation but also aligns with its mission to drive innovation in healthcare technology. As the industry evolves, the company plans to stay at the forefront, harnessing data to improve patient outcomes and streamline healthcare operations.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…